NICOLE WHITMAN: Open Payments
NPI 1063866937 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$338 in 20 payments from 10 companies in 2025. Trend: 2023 $291 · 2024 $468 · 2025 $338
Food & beverage: $338
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $138 |
| Novo Nordisk Inc | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Lilly USA, LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Exact Sciences Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Amgen Inc. | 1 | $15 |
Products named: AIRSUPRA, FARXIGA, GEMTESA, Ozempic, MOUNJARO, TRELEGY ELLIPTA, Wegovy, CAPLYTA.
Industry payments across MS — which companies pay providers there.
